Answers are grounded in this paper and cite their sources.
To evaluate the association of PIGF and sFlt-1 with low birth weight and/or small-for-gestational age neonates in pregnancy with or without preeclampsia. Singleton pregnancies with sFlt-1/PlGF tested were included and set into four groups for case–control analysis. Distribution of sFlt-1/PlGF, sFlt-1, PlGF, and PGF% were evaluated, Kruskal–Wallis test and Mann–Whitney U test were adopted for significance analysis. Maternal sFlt-1/PlGF, PlGF, PlGF%, and sFlt-1 were statistically associated with low birth weight and/or small-for-gestational age in pregnancy complicated or uncomplicated with preeclampsia. A significant difference was shown on sFlt-1/PIGF (p = 0.0082), PIGF% (p = 0.0326), PIGF (p = 0.0128), and sFlt-1 (p = 0.0469) in pregnancy with small-for-gestational age and/or low birth weight neonates. A significantly higher median of sFlt-1/PlGF (448 vs. 61.6, p < 0.0001) and sFlt-1 (15499 vs. 3226, p < 0.0001), a significantly lower median of PlGF (33.92 vs. 115.2, p < 0.0001) and PlGF% (−76.63 vs. −20.31, p < 0.0001) were demonstrated, respectively, when preeclampsia with small-for-gestational age and/or low birth weight neonates was compared with preeclampsia with normal birth weight neonates. No significant difference was demonstrated between low birth weight and small-for-gestational age on sFlt-1/PlGF, PlGF, PlGF%, and sFlt-1. sFlt-1/PlGF seems to be a promising biomarker in predicting low birth weight and/or small-for-gestational age neonates in pregnancy with or without preeclampsia.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: